tiprankstipranks
Trending News
More News >
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
US Market

NewAmsterdam Pharma Company (NAMS) Income Statement

Compare
239 Followers

NewAmsterdam Pharma Company Income Statement

Last quarter (Q3 2025), NewAmsterdam Pharma Company's total revenue was $348.00K, a decrease of -98.80% from the same quarter last year. In Q3, NewAmsterdam Pharma Company's net income was $-72.00M. See NewAmsterdam Pharma Company’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 45.56M$ 14.09M$ 102.69M$ 0.00$ 0.00
Gross Profit
$ 45.56M$ 14.09M$ 102.69M$ 0.00$ 0.00
Operating Expenses
$ 221.85M$ 197.06M$ 106.25M$ 34.98M$ 6.63M
Depreciation and Amortization
$ 113.00K$ 49.00K$ 9.00K$ 5.00K$ 1.22K
EBITDA
$ -241.49M$ -176.86M$ -22.34M$ -41.37M$ -6.63M
Operating Income
$ -176.29M$ -182.97M$ -3.56M$ -34.98M$ -6.63M
Other Income/Expenses
$ -65.31M$ 6.06M$ -19.08M$ -6.81M$ -390.91K
Pretax Income
$ -241.60M$ -176.91M$ -22.63M$ -41.78M$ -7.02M
Net Income
$ -241.60M$ -176.94M$ -22.63M$ -41.78M$ -7.02M
Per Share Metrics
Basic EPS
$ -2.56$ -2.15$ -1.11$ -3.34$ -1.15
Diluted EPS
$ -2.56$ -2.15$ -1.11$ -3.34$ -1.15
Weighted Average Shares Outstanding
94.36M 82.16M 18.97M 17.75M 17.75M
Weighted Average Shares Outstanding (Diluted)
94.36M 82.16M 18.97M 17.75M 17.75M
Currency in USD

NewAmsterdam Pharma Company Earnings and Revenue History